Nuo Therapeutics, Inc. Share Price

Equities

AURX

US67059V2097

Biotechnology & Medical Research

Market Closed - OTC Markets 09:51:21 25/04/2024 pm IST 5-day change 1st Jan Change
0.8 USD 0.00% Intraday chart for Nuo Therapeutics, Inc. 0.00% +45.45%
Sales 2022 112K 9.37M Sales 2023 609K 50.78M Capitalization 24.33M 2.03B
Net income 2022 -3M -250M Net income 2023 -3M -250M EV / Sales 2022 543 x
Net cash position 2022 1.72M 143M Net cash position 2023 673K 56.16M EV / Sales 2023 38.9 x
P/E ratio 2022
-18.9 x
P/E ratio 2023
-7.3 x
Employees 9
Yield 2022 *
-
Yield 2023
-
Free-Float 39.31%
More Fundamentals * Assessed data
Dynamic Chart
Current month-11.11%
1 month-11.11%
3 months+37.81%
6 months+60.00%
Current year+45.45%
More quotes
1 week
0.80
Extreme 0.8
0.80
1 month
0.75
Extreme 0.75
0.98
Current year
0.48
Extreme 0.48
0.98
1 year
0.40
Extreme 0.401
2.25
3 years
0.00
Extreme 0.0001
4.50
5 years
0.00
Extreme 0.0001
4.50
10 years
0.00
Extreme 0.0001
4.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 19/08/19
Chief Operating Officer 58 01/08/01
Members of the board TitleAgeSince
Director/Board Member 67 30/09/30
Chief Executive Officer 61 19/08/19
Director/Board Member 75 07/17/07
More insiders
Date Price Change Volume
25/24/25 0.8 0.00% 500

Delayed Quote OTC Markets, April 25, 2024 at 09:51 pm IST

More quotes
Nuo Therapeutics, Inc. is a regenerative therapies company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. Its flagship product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. The Company’s commercial offering consists of point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix (the Aurix System), which produces a platelet rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
More about the company